Skip to Main Content

Author Details

Ramana V Davuluri
The Wistar Institute
1999
121
54
PMIDPaper TitleJournal TitlePublished Year
37141575Rapid, High-Throughput Single-Cell Multiplex In Situ Tagging (MIST) Analysis of Immunological Disease with Machine Learning.Anal Chem2023
37965571Epithelial-mesenchymal transition: an organizing principle of mammalian regeneration.Front Cell Dev Biol2023
37509311Integrated Multi-Omic Analysis Reveals Immunosuppressive Phenotype Associated with Poor Outcomes in High-Grade Serous Ovarian Cancer.Cancers (Basel)2023
37424943Deep multi-omics integration by learning correlation-maximizing representation identifies prognostically stratified cancer subtypes.Bioinform Adv2023
35671108Epigenetic priming enhances antitumor immunity in platinum-resistant ovarian cancer.J Clin Invest2022
33473123Distinct mechanisms control genome recognition by p53 at its target genes linked to different cell fates.Nat Commun2021
33903225RP58 Represses Transcriptional Programs Linked to Nonneuronal Cell Identity and Glioblastoma Subtypes in Developing Neurons.Mol Cell Biol2021
33538820DNABERT: pre-trained Bidirectional Encoder Representations from Transformers model for DNA-language in genome.Bioinformatics2021
33692132A first-in-human phase 0 clinical study of RNA interference-based spherical nucleic acids in patients with recurrent glioblastoma.Sci Transl Med2021
34014317ExTraMapper: exon- and transcript-level mappings for orthologous gene pairs.Bioinformatics2021
33172933Frizzled-7 Identifies Platinum-Tolerant Ovarian Cancer Cells Susceptible to Ferroptosis.Cancer Res2021
33406077Personizing the prediction of future susceptibility to a specific disease.PLoS One2021
32984664Identification of Geographic Specific SARS-Cov-2 Mutations by Random Forest Classification and Variable Selection Methods.Stat Appl2020
31924844In silico analysis of alternative splicing on drug-target gene interactions.Sci Rep2020
32606006FTO-Dependent N [6]-Methyladenosine Modifications Inhibit Ovarian Cancer Stem Cell Self-Renewal by Blocking cAMP Signaling.Cancer Res2020
30613765IDH3α regulates one-carbon metabolism in glioblastoma.Sci Adv2019
31815646Immune landscapes associated with different glioblastoma molecular subtypes.Acta Neuropathol Commun2019
31920606Multivariate Analysis of Preoperative Magnetic Resonance Imaging Reveals Transcriptomic Classification of <i>de novo</i> Glioblastoma Patients.Front Comput Neurosci2019
31118097Transcriptional consequences of impaired immune cell responses induced by cystic fibrosis plasma characterized via dual RNA sequencing.BMC Med Genomics2019
31002564Platform-Independent Classification System to Predict Molecular Subtypes of High-Grade Serous Ovarian Carcinoma.JCO Clin Cancer Inform2019
29311577Publisher Correction: Transcribed ultraconserved region 339 promotes carcinogenesis by modulating tumor suppressor microRNAs.Nat Commun2018
29875463Metastatic cancers promote cachexia through ZIP14 upregulation in skeletal muscle.Nat Med2018
29572492Radiomic MRI signature reveals three distinct subtypes of glioblastoma with different clinical and molecular characteristics, offering prognostic value beyond IDH1.Sci Rep2018
29568390Characterization of brain tumor initiating cells isolated from an animal model of CNS primitive neuroectodermal tumors.Oncotarget2018
26944083Comparative evaluation of isoform-level gene expression estimation algorithms for RNA-seq and exon-array platforms.Brief Bioinform2017
28134249Orthogonal ubiquitin transfer identifies ubiquitination substrates under differential control by the two ubiquitin activating enzymes.Nat Commun2017
28249000Stabilization of HIF-1α and HIF-2α, up-regulation of MYCC and accumulation of stabilized p53 constitute hallmarks of CNS-PNET animal model.PLoS One2017
28096648Identification of Genetic and Epigenetic Variants Associated with Breast Cancer Prognosis by Integrative Bioinformatics Analysis.Cancer Inform2017
29180617Transcribed ultraconserved region 339 promotes carcinogenesis by modulating tumor suppressor microRNAs.Nat Commun2017
28564604Cancer-Associated IDH1 Promotes Growth and Resistance to Targeted Therapies in the Absence of Mutation.Cell Rep2017
27903673Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers.Clin Cancer Res2017
26188015Imaging patterns predict patient survival and molecular subtype in glioblastoma via machine learning techniques.Neuro Oncol2016
27364770MNK Inhibition Disrupts Mesenchymal Glioma Stem Cells and Prolongs Survival in a Mouse Model of Glioblastoma.Mol Cancer Res2016
27409348Identification and validation of regulatory SNPs that modulate transcription factor chromatin binding and gene expression in prostate cancer.Oncotarget2016
25355877Shift in monocyte apoptosis with increasing viral load and change in apoptosis-related ISG/Bcl2 family gene expression in chronically HIV-1-infected subjects.J Virol2015
26576613Evaluation of data discretization methods to derive platform independent isoform expression signatures for multi-class tumor subtyping.BMC Genomics2015
26470881Gene expression profiling of the human natural killer cell response to Fc receptor activation: unique enhancement in the presence of interleukin-12.BMC Med Genomics2015
26046767Identification of Reprogrammed Myeloid Cell Transcriptomes in NSCLC.PLoS One2015
26041838Correction for Patro et al., Shift in Monocyte Apoptosis with Increasing Viral Load and Change in Apoptosis-Related ISG/Bcl2 Family Gene Expression in Chronically HIV-1-Infected Subjects.J Virol2015
25934697Sprouty2 Drives Drug Resistance and Proliferation in Glioblastoma.Mol Cancer Res2015
25303483Genetic predisposition to papillary thyroid carcinoma: involvement of FOXE1, TSHR, and a novel lincRNA gene, PTCSC2.J Clin Endocrinol Metab2015
24121688CTCF binding site sequence differences are associated with unique regulatory and functional trends during embryonic stem cell differentiation.Nucleic Acids Res2014
25299576Protein kinase A activation enhances β-catenin transcriptional activity through nuclear localization to PML bodies.PLoS One2014
25030914Genome-wide mapping of RNA Pol-II promoter usage in mouse tissues by ChIP-seq.Methods Mol Biol2014
24503249Isoform-level gene signature improves prognostic stratification and accurately classifies glioblastoma subtypes.Nucleic Acids Res2014
24676094Subtelomeric CTCF and cohesin binding site organization using improved subtelomere assemblies and a novel annotation pipeline.Genome Res2014
24368849miR-218 opposes a critical RTK-HIF pathway in mesenchymal glioblastoma.Proc Natl Acad Sci U S A2014
23796952CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer.Genome Res2013
24037088HINCUTs in cancer: hypoxia-induced noncoding ultraconserved transcripts.Cell Death Differ2013
23826213Global Identification of EVI1 Target Genes in Acute Myeloid Leukemia.PLoS One2013
  • 1 - 50 of 121

Recommended Authors

Venkat S Malladi
UT Southwestern Medical Center
Career Start Year 2008
Number of shared co-authors 4
Yue Lu
The University of Texas MD Anderson Cancer Center
Career Start Year 2006
Number of shared co-authors 3
Altuna Akalin
Berlin Institute for Medical Systems Biology
Career Start Year 2006
Number of shared co-authors 1
Chao Cheng
Baylor College of Medicine
Career Start Year 2005
Number of shared co-authors 2
David J Arenillas
BC Children's Hospital Research Institute, University of British Columbia
Career Start Year 2005
Number of shared co-authors 1
Sebastian Schmeier
Massey University
Career Start Year 2004
Number of shared co-authors 0
Xianghong Jasmine Zhou
David Geffen School of Medicine, University of California at Los Angeles
Career Start Year 2004
Number of shared co-authors 0
Quaid Morris
Sloan Kettering Institute
Career Start Year 2003
Number of shared co-authors 0
Pavel Sumazin
Baylor College of Medicine
Career Start Year 2003
Number of shared co-authors 2
Pedro A F Galante
Hospital Sirio Libanes
Career Start Year 2003
Number of shared co-authors 0
Zhaolei Zhang
University of Toronto
Career Start Year 2002
Number of shared co-authors 0
Zhaohui S Qin
Emory University
Career Start Year 2002
Number of shared co-authors 2
Carsten O Daub
International Institute of Molecular and Cell Biology in Warsaw
Career Start Year 2002
Number of shared co-authors 0
Albin Sandelin
University of Copenhagen
Career Start Year 2002
Number of shared co-authors 2
Yidong Chen
The University of Texas Health Science Center at San Antonio
Career Start Year 2001
Number of shared co-authors 4
Mikhail G Dozmorov
Virginia Commonwealth University
Career Start Year 2001
Number of shared co-authors 0
Terrence S Furey
University of North Carolina at Chapel Hill
Career Start Year 2000
Number of shared co-authors 4
Ru-Fang Yeh
Genentech Inc.
Career Start Year 1999
Number of shared co-authors 3
Zhongming Zhao
Center for Precision Health, The University of Texas Health Science Center at Houston
Career Start Year 1998
Number of shared co-authors 7
Laura Elnitski
National Human Genome Research Institute
Career Start Year 1997
Number of shared co-authors 4
Panayiotis V Benos
University of Florida
Career Start Year 1996
Number of shared co-authors 1
Steven J M Jones
University of British Columbia
Career Start Year 1995
Number of shared co-authors 17
Alistair R R Forrest
RIKEN Center for Integrative Medical Sciences
Career Start Year 1994
Number of shared co-authors 0
Jill P Mesirov
University of California San Diego
Career Start Year 1992
Number of shared co-authors 5
Wing Hung Wong
Stanford University
Career Start Year 1991
Number of shared co-authors 1
Sean M Grimmond
The University of Melbourne
Career Start Year 1990
Number of shared co-authors 4
John Quackenbush
Harvard T. H. Chan School of Public Health
Career Start Year 1989
Number of shared co-authors 3
Harukazu Suzuki
RIKEN Center for Integrative Medical Sciences
Career Start Year 1985
Number of shared co-authors 0
Hideya Kawaji
RIKEN Center for Integrative Medical Sciences
Career Start Year 1984
Number of shared co-authors 0
Tatsuhiko Tsunoda
The University of Tokyo
Career Start Year 1984
Number of shared co-authors 2

Collaborators

Yingtao Bi
Foundational Immunology, AbbVie Cambridge Research Center
Co-authored papers 21
Sandya Liyanarachchi
The Ohio State University Comprehensive Cancer Center, Comprehensive Cancer Center
Co-authored papers 19
Tim H-M Huang
University of Texas Health San Antonio (UTHSA)
Co-authored papers 14
Sharmistha Pal
Co-authored papers 12
Christoph Plass
German Cancer Research Center
Co-authored papers 11
Manoj Kandpal
Center for Clinical and Translational Science, Rockefeller University
Co-authored papers 8
Albert de la Chapelle
The Ohio State University Comprehensive Cancer Center
Co-authored papers 7
Nadia Dahmane
Weill Cornell Medical College
Co-authored papers 7
Donald M O'Rourke
Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania
Co-authored papers 6
Francisco A Perez
Seattle Children's Hospital
Co-authored papers 6
Louise C Showe
The Wistar Institute
Co-authored papers 6
Mircea Ivan
Indiana University School of Medicine
Co-authored papers 4
Cristina Ivan
The University of Texas MD Anderson Cancer Center
Co-authored papers 4
Craig Horbinski
Co-authored papers 4
Michael Q Zhang
Co-authored papers 4
Rebecca Nagy
Guardant Health Inc.
Co-authored papers 3
Charles D James
Co-authored papers 3
Lianbo Yu
The Ohio State University
Co-authored papers 3
Huiling He
The Ohio State University Comprehensive Cancer Center
Co-authored papers 3
Valérie Baubet
Co-authored papers 3
Maria Martinez-Lage
Massachusetts General Hospital
Co-authored papers 3
Christos Davatzikos
University of Pennsylvania
Co-authored papers 3
Yutaka Suzuki
Co-authored papers 2
Wei Li
The Ohio State University
Co-authored papers 2
Wei Zhang
The University of Texas MD Anderson Cancer Center
Co-authored papers 2
Mareike Simon
Abramson Family Cancer Research Institute, Perelman School of Medicine
Co-authored papers 2
Joel Saltz
Stony Brook University
Co-authored papers 2
Laura Z Rassenti
University of California San Diego
Co-authored papers 2
Han Liang
MD Anderson Cancer Center
Co-authored papers 2
Sumio Sugano
Co-authored papers 2
Release 1.2